AstraZeneca Pharma India receives DCGI's approval for import of cancer drug
The approval is based on a global, head-to-head, randomised, open label, registrational Phase III trial, DESTINY Breast 0304-05-2023
04-05-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Astrazeneca Pharma India Limited Has Received A Permission In Form CT-20 To Import For Sale And Distribution Of Trastuzumab Deruxtecan (Enhertu) 100Mg/5Ml Vial Lyophilized Powder For Concentrate For Solution For Infusion
Please find the enclosed letter of the Company in relation to the captioned subject for your reference.03-05-2023
AstraZeneca to set up centers of excellence for severe asthma in India
The centres will serve as the hub for treatment and management of severe asthma patients, and they will, in turn, guide and support evolving severe asthma centres for a systematic and guidelines-based approach to identify and treat severe asthma patients02-05-2023
US FDA panel backs restricted use of AstraZeneca's prostate cancer drug
Lynparza is already approved by the FDA to treat a type of breast cancer, ovarian cancer, as well as a different form of prostate cancer01-05-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyASTRAZENECA PHARMA INDIA LTD. 2CIN NO.L24231KA1979PLC003563 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Manasa R Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Rajesh Marwaha Designation: Chief Financial Officer and Director EmailId: [email protected] Date: 25/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.25-04-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the legal representative of the claimant.14-04-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
As required under Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we furnish herewith a Certificate issued by the Practicing Company Secretary with regard to transfer of securities effected during the year ended March 31, 2023. Please take the above document on record.13-04-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to certify that, Integrated Registry Management Services Private Limited are the Company's Registrar and Transfer Agents and that all activities in relation to the share transfer are maintained by Integrated Registry Management Services Private Limited We are also attaching the certificate received from our Registrar and Transfer Agents, Integrated Registry Management Services Private Limited along with this letter. This is for your information and records.13-04-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated April 5, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. Please take the same on record.13-04-2023
Serum Institute restarts manufacturing of Covishield vaccine as Covid cases surge
The Serum Institute was among the first two vaccine manufacturers who rolled out Covid vaccines in India. Pune-based Serum produced Covishield in partnership with UK's AstraZeneca while Hyderabad-based Bharat Biotech rolled out Covaxin.12-04-2023